JP2004534093A - フルベストラントの筋肉内投与用の医薬製剤 - Google Patents
フルベストラントの筋肉内投与用の医薬製剤 Download PDFInfo
- Publication number
- JP2004534093A JP2004534093A JP2003511869A JP2003511869A JP2004534093A JP 2004534093 A JP2004534093 A JP 2004534093A JP 2003511869 A JP2003511869 A JP 2003511869A JP 2003511869 A JP2003511869 A JP 2003511869A JP 2004534093 A JP2004534093 A JP 2004534093A
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- weight
- volume
- fulvestrant
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims abstract description 166
- 229960002258 fulvestrant Drugs 0.000 title claims abstract description 164
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 96
- 238000007918 intramuscular administration Methods 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 272
- 239000000203 mixture Substances 0.000 claims abstract description 170
- 238000009472 formulation Methods 0.000 claims abstract description 152
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 claims abstract description 35
- 229940066675 ricinoleate Drugs 0.000 claims abstract description 35
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000002347 injection Methods 0.000 claims abstract description 17
- 239000007924 injection Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 15
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 282
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 204
- 229960002903 benzyl benzoate Drugs 0.000 claims description 102
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 94
- 239000004359 castor oil Substances 0.000 claims description 85
- 235000019438 castor oil Nutrition 0.000 claims description 85
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 85
- 239000013020 final formulation Substances 0.000 claims description 69
- 239000003937 drug carrier Substances 0.000 claims description 43
- 239000007927 intramuscular injection Substances 0.000 claims description 38
- 238000010255 intramuscular injection Methods 0.000 claims description 35
- 239000000654 additive Substances 0.000 claims description 33
- 230000000996 additive effect Effects 0.000 claims description 27
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000003211 malignant effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 5
- 210000005000 reproductive tract Anatomy 0.000 claims description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 4
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 4
- 229940093471 ethyl oleate Drugs 0.000 claims description 4
- 229940074928 isopropyl myristate Drugs 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- 229940075495 isopropyl palmitate Drugs 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 12
- -1 4,4,5,5,5-pentafluoropentylsulfinyl Chemical group 0.000 abstract description 6
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 5
- 238000013268 sustained release Methods 0.000 abstract description 3
- 239000012730 sustained-release form Substances 0.000 abstract description 3
- 229960004756 ethanol Drugs 0.000 description 75
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229940011871 estrogen Drugs 0.000 description 11
- 239000000262 estrogen Substances 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 239000000328 estrogen antagonist Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940046836 anti-estrogen Drugs 0.000 description 9
- 230000001833 anti-estrogenic effect Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 150000003431 steroids Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 150000001298 alcohols Chemical class 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000003637 steroidlike Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 239000003759 ester based solvent Substances 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 2
- 229960003656 ricinoleic acid Drugs 0.000 description 2
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001836 utereotrophic effect Effects 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229940027974 fulvestrant 50 mg/ml Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0116619.8A GB0116619D0 (en) | 2001-07-07 | 2001-07-07 | Formulation |
| US31571101P | 2001-08-30 | 2001-08-30 | |
| PCT/GB2002/003092 WO2003006064A1 (en) | 2001-07-07 | 2002-07-03 | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004534093A true JP2004534093A (ja) | 2004-11-11 |
Family
ID=26246290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003511869A Pending JP2004534093A (ja) | 2001-07-07 | 2002-07-03 | フルベストラントの筋肉内投与用の医薬製剤 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1406662A1 (ru) |
| JP (1) | JP2004534093A (ru) |
| CN (1) | CN1553815A (ru) |
| AR (1) | AR037138A1 (ru) |
| BR (1) | BR0210898A (ru) |
| CA (1) | CA2453111A1 (ru) |
| CO (1) | CO5560585A2 (ru) |
| HU (1) | HUP0400115A3 (ru) |
| IL (1) | IL159576A0 (ru) |
| IS (1) | IS7097A (ru) |
| MX (1) | MXPA04000028A (ru) |
| NO (1) | NO20040047L (ru) |
| PL (1) | PL367624A1 (ru) |
| RU (1) | RU2004102393A (ru) |
| WO (1) | WO2003006064A1 (ru) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015511606A (ja) * | 2012-03-31 | 2015-04-20 | リポント ファーマシューティカルズ インコーポレイテッド | 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法 |
| WO2017175810A1 (ja) * | 2016-04-06 | 2017-10-12 | 富士フイルム株式会社 | 医薬組成物 |
| JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク． | フルベストラント配合物およびその使用方法 |
| US10668083B2 (en) | 2016-05-31 | 2020-06-02 | Fujifilm Corporation | Pharmaceutical composition |
| JP2021502362A (ja) * | 2017-11-08 | 2021-01-28 | イーグル ファーマスーティカルズ、インク． | フルベストラント製剤とその使用方法 |
| JP2023504867A (ja) * | 2019-12-11 | 2023-02-07 | 上海博志研新薬物技術有限公司 | フルベストラント医薬組成物、その調製方法及び応用 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| CN102264372B (zh) | 2009-08-31 | 2012-07-11 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| CN102600065B (zh) * | 2012-03-31 | 2014-08-13 | 莱普德制药有限公司 | 一种氟维司群或其衍生物油性制剂及其制备方法 |
| CN102600064A (zh) * | 2012-03-31 | 2012-07-25 | 西安力邦制药有限公司 | 氟维司群或其衍生物缓释制剂及其制备方法 |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| US20210169897A1 (en) * | 2017-12-07 | 2021-06-10 | Nevakar Inc. | Concentrated Fulvestrant Compositions |
| CN111465398A (zh) * | 2018-01-31 | 2020-07-28 | 富士胶片株式会社 | 注射用制剂的制造方法 |
| CN111481559B (zh) * | 2019-01-25 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种高浓度的氟维司群组合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8813353D0 (en) * | 1988-06-06 | 1988-07-13 | Ici Plc | Therapeutic product |
| GB9525194D0 (en) * | 1995-12-12 | 1996-02-07 | Zeneca Ltd | Pharmaceutical composition |
| GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
-
2002
- 2002-07-03 IL IL15957602A patent/IL159576A0/xx unknown
- 2002-07-03 WO PCT/GB2002/003092 patent/WO2003006064A1/en not_active Application Discontinuation
- 2002-07-03 RU RU2004102393/15A patent/RU2004102393A/ru not_active Application Discontinuation
- 2002-07-03 BR BR0210898-4A patent/BR0210898A/pt not_active IP Right Cessation
- 2002-07-03 PL PL02367624A patent/PL367624A1/xx not_active Application Discontinuation
- 2002-07-03 JP JP2003511869A patent/JP2004534093A/ja active Pending
- 2002-07-03 CN CNA028171888A patent/CN1553815A/zh active Pending
- 2002-07-03 CA CA002453111A patent/CA2453111A1/en not_active Abandoned
- 2002-07-03 EP EP02740940A patent/EP1406662A1/en not_active Withdrawn
- 2002-07-03 HU HU0400115A patent/HUP0400115A3/hu unknown
- 2002-07-05 AR ARP020102523A patent/AR037138A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 IS IS7097A patent/IS7097A/is unknown
- 2004-01-06 NO NO20040047A patent/NO20040047L/no not_active Application Discontinuation
- 2004-01-07 CO CO04000761A patent/CO5560585A2/es not_active Application Discontinuation
- 2004-01-07 MX MXPA04000028A patent/MXPA04000028A/es unknown
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015511606A (ja) * | 2012-03-31 | 2015-04-20 | リポント ファーマシューティカルズ インコーポレイテッド | 乳酸エステルをベースとするフルベストラント又はその誘導体の油性製剤およびその製造方法 |
| US10568890B2 (en) | 2012-03-31 | 2020-02-25 | Xi'an Libang Pharmaceutical Co., Ltd | Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method thereof |
| WO2017175810A1 (ja) * | 2016-04-06 | 2017-10-12 | 富士フイルム株式会社 | 医薬組成物 |
| JPWO2017175810A1 (ja) * | 2016-04-06 | 2018-12-20 | 富士フイルム株式会社 | 医薬組成物 |
| US10772895B2 (en) | 2016-04-06 | 2020-09-15 | Fujifilm Corporation | Pharmaceutical composition |
| JP2019516789A (ja) * | 2016-05-06 | 2019-06-20 | イーグル ファーマスーティカルズ、インク． | フルベストラント配合物およびその使用方法 |
| US10668083B2 (en) | 2016-05-31 | 2020-06-02 | Fujifilm Corporation | Pharmaceutical composition |
| JP2021502362A (ja) * | 2017-11-08 | 2021-01-28 | イーグル ファーマスーティカルズ、インク． | フルベストラント製剤とその使用方法 |
| JP7220712B2 (ja) | 2017-11-08 | 2023-02-10 | イーグル ファーマスーティカルズ、インク． | フルベストラント製剤とその使用方法 |
| JP2023504867A (ja) * | 2019-12-11 | 2023-02-07 | 上海博志研新薬物技術有限公司 | フルベストラント医薬組成物、その調製方法及び応用 |
| JP7497902B2 (ja) | 2019-12-11 | 2024-06-11 | 上海雲晟研新生物科技有限公司 | フルベストラント医薬組成物、その調製方法及び応用 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400115A2 (hu) | 2004-06-28 |
| AR037138A1 (es) | 2004-10-27 |
| NO20040047L (no) | 2004-02-23 |
| HUP0400115A3 (en) | 2005-11-28 |
| MXPA04000028A (es) | 2004-05-21 |
| WO2003006064A1 (en) | 2003-01-23 |
| CN1553815A (zh) | 2004-12-08 |
| RU2004102393A (ru) | 2005-03-27 |
| CO5560585A2 (es) | 2005-09-30 |
| IL159576A0 (en) | 2004-06-01 |
| BR0210898A (pt) | 2004-06-22 |
| PL367624A1 (en) | 2005-03-07 |
| EP1406662A1 (en) | 2004-04-14 |
| IS7097A (is) | 2004-01-05 |
| CA2453111A1 (en) | 2003-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3713237B2 (ja) | フルベストラント製剤 | |
| JP2004534093A (ja) | フルベストラントの筋肉内投与用の医薬製剤 | |
| JP4295087B2 (ja) | フルベストラントを含む製剤 | |
| KR20040010841A (ko) | 풀베스트란트의 근육내 주사용 약학 제제 | |
| AU2002314368A1 (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant |